INTRESO's New Fumigation Treatment Approved in U.S. as a High-Efficacy Alternative to the Damaging Methyl Bromide
10.9.2025 15:00:00 CEST | Business Wire | Press Release
International Treatment Solutions (INTRESO) Group is pleased to announce the registration of eFUME® by the U.S. Environmental Protection Agency (EPA). The registration marks an important milestone for the U.S. agricultural sector in safeguarding its supply chains and biosecurity.
eFUME® is a fast-acting, safe, and effective solution for protecting post-harvest produce, packaged and stored foods, and processing equipment. Suited to a wide variety of fruits, vegetables, grains, and cut flowers, its active ingredient, ethyl formate, is a naturally occurring substance. It is regarded as safe for human health by the U.S. Food and Drug Administration (FDA), yet rapidly and effectively eliminates insect pests, typically within one to 24 hours, resulting in no withholding period and faster shipping.
Designed for broad applications, eFUME® is effective against stored product insects, fresh produce pests, mites, quarantine pests of concern, and household insects. It is already registered and widely used in Australia and New Zealand – two leading global agricultural exporters. The list of regulatory approvals for eFUME® is expanding rapidly as demand for sustainable pest management solutions grows.
Crucially, eFUME® is a direct, cost-effective, drop-in replacement for methyl bromide, an ozone-depleting substance (ODS), banned by the 1987 Montreal Protocol on Substances that Deplete the Ozone Layer. Owing to its classification as an ODS, in 2005, the U.S., along with other countries, committed to phase out the production and consumption of methyl bromide.
This registration of a viable alternative is therefore an important positive step taken by the U.S authorities, giving food producers, fumigators, and agricultural supply chain operators the opportunity to use a cost efficient, safe, and highly effective product while reducing their impact on the environment. It will protect the integrity of U.S. eco-systems, ensuring U.S. farmers, food producers and importers can keep their produce pest-free throughout the supply chain.
Responding to the news, Kade McConville, Executive Director of INTRESO, said:
“I welcome the EPA’s approval of eFUME®, which has come following years of rigorous assessment of safety and efficacy against the highest modern standards. This decision marks a major step forward for the U.S. agricultural sector, and we see huge excitement within industry for an effective, sustainable alternative to methyl bromide. This registration also highlights the growing demand from regulators, as well as the broader supply chain, for innovative solutions that increase effectiveness and align with global environmental priorities.
Shannon Sked at Western Fumigation said: “I am delighted that the EPA has approved eFUME®, for commercial use in the U.S. For too long, the agricultural sector has had no choice but to use legacy products; the addition of eFUME®, adds a more environmentally friendly alternative to the options that the USDA can implement. I am proud to be incorporating eFUME® into our operational model to continue our mission of protecting domestic agriculture from catastrophic invasive species introduction while ensuring nutritious food availability for American families.”
About INTRESO
INTRESO Group is a leader in developing and commercialising environmentally sustainable treatment solutions for the agricultural sector. The company provides global expertise in product commercialisation, product registration, and market development, helping manufacturers, suppliers, distributors, and customers bring new technologies to market. Its portfolio of advanced fumigants and biocides – EDN®, BLUEFUME®, and eFUME® – sets a benchmark for sustainable alternatives to traditional practices. By bridging innovation with regulatory approval and commercial rollout, INTRESO enables the adoption of safe, effective, and future-focused solutions across global supply chains.
About eFUME®
eFUME® (active ingredient: Ethyl Formate) is manufactured by INTRESO and is a safe, non-residual way to protect your post-harvest produce, packaged and stored foods and processing equipment. The active ingredient is Ethyl Formate – a naturally occurring, non-residual substance with no ozone depleting potential.
Ethyl Formate is generally regarded as safe (GRAS) by the American Food and Drug Administration (FDA). It has low mammalian toxicity but rapidly kills insect pests. It is approved in several countries for control of insect pests for post-harvest commodities.
eFUME® has been developed for a broad range of applications from post-harvest fumigation household pests to equipment disinfestation. It is suited to a wide variety of fruits, vegetables, grains, cut flowers, and the list of regulatory approvals is expanding rapidly.
eFUME® has also been approved by the Australian Department of Agriculture, Forestry, and Fisheries (DAFF) and New Zealand Ministry of Primary Industries (NZMPI) for the treatment of Brown Marmorated Stink Bug (BMSB) as a seasonal control measure.
References
- Ozone-depleting impact of methyl bromide: Ozone-Depleting Substances | U.S. EPA
- University of Reading study on global warming potential of alternative fumigants: https://centaur.reading.ac.uk/112038/
- The U.S. use of methyl bromide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910281003/en/
Contacts
Kade McConville (Kade.McConville@draslovka.com)
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom